New Products: Bakon Vodka

Bakon Vodka

Bakon Vodka, the first commercially available bacon-flavored vodka, is created from Idaho potatoes and is column-distilled using a single heating process that doesn’t “bruise” the alcohol. The delicate balance of flavors leaves drinkers with the essence of a crisp slice of peppered bacon. Bakon Vodka is available in limited quantities in Washington, Oregon, Idaho and Montana.

For more information, visit

Herradura Blue Agave Nectar

Herradura Blue Agave Nectar, from the makers of Tequila Herradura, is a natural sweetener that can be used as a replacement for simple syrup. Its long shelf life and lower glycemic index make it a strong, safe alternative to sugar. The nectar is made by cooking and filtering the sap from the heart of the blue agave plant. Its taste is similar to honey but less viscous, so it can be used to sweeten cold drinks.

For more information, visit

Newcastle Summer Ale

Newcastle Summer Ale, the first seasonal ale from Newcastle, is available for a limited time. Summer Ale is a draught beer available in select markets until mid-September. The light-colored ale infuses Golden Promise and Optic Malts to provide a hoppier taste. It also blends Fuggles and Super Styrian Goldings Hops. For greater promotion possibilities, Newcastle Summer Ale glassware, with a wider rim and new logo celebrating “Hops and Glory,” also is available.

For more information, visit

Nostalgic Chandelier Bulbs

Designed for a romantic, old world look, Bulbrite has unveiled Nostalgic Chandelier Bulbs. The new Flame and Torpedo profiles are ideal for romantic chandeliers, traditional lanterns and old world fixtures for a unique, nostalgic look. Available in 15-watt versions, Nostalgic Chandelier Bulbs offer a warm amber color and filament and a unique look of yesteryear.

For more information, visit

Suggested Articles

A breakdown of the latest $1 trillion from the Senate.

The number of businesses switching from temporary to permanent closures surpasses 50%.

The coronavirus continues to threaten our industry but there are promising medical developments and still many questions on the next round of relief.